Company

Oncolytics Biotech Inc.

Headquarters: Calgary, AB, Canada

Employees: 26

CEO: Dr. Matthew C. Coffey

TSX: ONC -5.41%

Market Cap

C$105.6 Million

CAD as of July 1, 2024

US$76.9 Million

Market Cap History

Oncolytics Biotech Inc. market capitalization over time

Evolution of Oncolytics Biotech Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Oncolytics Biotech Inc.

Detailed Description

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Oncolytics Biotech Inc. has the following listings and related stock indices.


Stock: TSX: ONC wb_incandescent

Stock: NASDAQ: ONCY wb_incandescent

Stock: FSX: ONYN wb_incandescent

Details

Headquarters:

1167 Kensington Crescent NW

Suite 210

Calgary, AB T2N 1X7

Canada

Phone: 403 670 7377